Paclitacxel and carboplatin in advanced non-small-cell lung cancer
	    		
		   		
	    	
    	
    	
   		
        
        	
        		- VernacularTitle:紫杉醇联合卡铂治疗晚期非小细胞肺癌
 
        	
        	
        	
        		- Author:
	        		
		        		
		        		
			        		Puwen HUANG
			        		
			        		;
		        		
		        		
		        		
			        		Yongqian SHU
			        		
			        		;
		        		
		        		
		        		
			        		Kaihua LU
			        		
			        		
		        		
		        		
		        		
		        		
		        		
			        		
			        		
		        		
	        		
        		 
        	
        	
        	
        		- Publication Type:Journal Article
 
        	
        	
        		- Keywords:
        			
	        			
	        				
	        				
			        		
				        		lung neoplasm;
			        		
			        		
			        		
				        		non-small-cell lung cancer;
			        		
			        		
			        		
				        		paclitacxel;
			        		
			        		
			        		
				        		carboplatin
			        		
			        		
	        			
        			
        		
 
        	
            
            
            	- From:
	            		
	            			China Oncology
	            		
	            		 1998;0(04):-
	            	
            	
 
            
            
            	- CountryChina
 
            
            
            	- Language:Chinese
 
            
            
            	- 
		        	Abstract:
			       	
			       		
				        
				        	Purpose:To evaluate the efficacy and toxicity of the combination of paclitacxel and carboplatin on advanced non-small-cell lung cancer (NSCLC). Methods:Forty-eight patients with locally advanced (stageⅢb) or metastatic (stage Ⅳ) NSCLC were enrolled into the study. The patients received paclitacxel 55-60 mg/m  2 on day 1,8,15, carboplatin at an AUC of 5 on day 1. administreted in a 28-day cycle. Results:An objective response was obtained in 37.5% of patients (2 complete and 16 partial responses),Significant difference existed between the naive patients and pretreated patients (46.4% Vs 25.0%,P